Additionally, we investigated the impact of G9a inhibition with UNC0642 and selective CB1R (ACEA) and/or CB2R (JWH133) agonists on cognitive decline and neuroinflammation in the SAMP8, a late-onset Alzheimer's disease (LOAD) mouse model [[48], [49], [50]]. The gene discussed is CNR1; the disease is early-onset autosomal dominant Alzheimer disease.